[Back to Overwiew]  [IACM Homepage]

IACM-Bulletin of 06 August 2006

Science: Nabilone effective in the treatment of chronic pain in clinical study

Physicians at a hospital in Vienna, Austria, conducted a placebo-controlled clinical study with nabilone in 30 patients who suffered from chronic therapy-resistant pain. During a 14 week period patients received nabilone and placebo each for four weeks in addition to their standard medication. Participants chose the dosage of the study drug themselves, between 1 and 4 capsules corresponding to 0.25-1 mg nabilone or placebo per day. In the following 16 weeks patients were allowed to freely choose their prefered drug (test drug A or B).

Nabilone is a synthetic cannabinoid with similar effects as the natural cannabinoid THC. The intake of nabilone was associated with a significant decrease in pain intensity of spinal origin, with a significant decrease of average headache intensity, and with an increase in quality of life. The number of study participants who favoured nabilone was more than 4 times higher than those who favoured placebo.

Researchers concluded "that a majority of patients with chronic pain classify nabilone intake in addition to the standard treatment as a measure with a positive individual benefit-risk-ratio. Thus, this kind of treatment may be an interesting and attractive enrichment of analgetic therapy concepts."

(Source: Pinsger M, Schimetta W, Volc D, Hiermann E, Riederer F, Polz W. [Benefits of an add-on treatment with the synthetic cannabinomimetic nabilone on patients with chronic pain - a randomized controlled trial.] [Article in German] Wien Klin Wochenschr 2006;118(11-12):327-35)

Canada: Health Canada looking for a new supplier of cannabis for medical use

In December 2000 the Canadian Government gave Prairie Plant Systems a five-year contract to supply cannabis to the health ministry (Health Canada) to be used for patients and clinical research. The contract was renewed until the end of September 2006. Now Health Canada is seeking proposals from further potential suppliers and invites interested companies and individuals to submit bids for a cannabis-growing contract.

This process could result in Prairie Plant Systems being selected again, or some other supplier could get the contract. Philippe Lucas, spokesman for the group Canadians for Safe Access, however noted that it might be better to leave the concept of a single supplier. People, who use medicinal marijuana respond better to different strains of the drug, Lucas said, and want the right to choose from a selection. About 280 patients currently receive the government cannabis, which Prairie Plant Systems grows in an unused section of a mine. Most patients buy 30-gram bags of cannabis for 150 Canadian Dollars (about 105 EURos).

(Source: Canadian Press of 27 July 2006)

Science: Topical application of a natural endocannabinoid effective in reducing pruritus in clinical study

Researchers of the University of Munster, Germany, conducted an open study with N-palmitoyl ethanolamine (PEA) in 22 patients with severe pruritus (itching) of several causes. PEA was applied in an emollient cream to the skin. It is an endocannabinoid that binds to cannabinoid receptors such as THC and other cannabinoids. These receptors are present in the skin.

In 14 of the 22 patients a good antipruritic effect could be documented. The average reduction in itch was 86.4 per cent. The therapy was well-tolerated by all patients without local or general side effects. Researchers concluded that "topical cannabinoid agonists represent a new effective and well-tolerated therapy for refractory itching of various origins. Creams with a higher concentration may be even more effective with broader indications."

(Source: Stander S, Reinhardt HW, Luger TA. [Topical cannabinoid agonists : An effective new possibility for treating chronic pruritus.] [Article in German] Hautarzt. 2006 Jul 28; [Electronic publication ahead of print])

News in brief

Science: ICRS meeting
The abstract book with the abstracts of the talks and posters at the past meeting of the ICRS (International Cannabinoid Research Society) in Hungary are now available online for download at:
cannabinoidsociety.org/symposium.2006/2006.icrs.program.and.abstracts.pdf

USA: California
With medical cannabis dispensaries under mounting pressure from law enforcement agencies, supporters have urged the San Diego City Council to call for a halt to federal raids, and to regulate the operation of the shops through local authorities. Local law enforcement agencies and federal drug agents raided several cannabis dispensaries on 7 July and made 15 arrests. On 21 July, federal agents visited 10 shops, confiscated cannabis and warned operators that they are operating illegally and could be arrested. Supporters of medical cannabis asked the city council to pass a resolution that would prohibit local authorities from assisting federal agencies in the arrest or prosecution of patients or dispensary operators. (Source: San Diego Union Tribune of 26 July 2006)

Science: Postoperative pain
Researchers of a hospital in Montreal, Canada, investigated the effects of nabilone on postoperative pain in a placebo controlled study. 45 patients received either 1 or 2 mg nabilone compared to placebo and another painkiller (ketoprofen) every eight hours for 24 hours following different surgeries. Total morphine consumption was not different in the four groups. Contrary to expectations the higher dose of nabilone increased pain instead of reducing it. (Source: Beaulieu P. Can J Anaesth 2006;53(8):769-75)

Science: Pregnancy
Researchers of the Vanderbilt University in Nashville, USA, investigated the effects of anandamide concentration on development of embryos and transport of eggs in mice. Higher than normal anandamide concentrations or application of THC disturbed both embryo development and transport of eggs. (Source: Wang H, et al. J Clin Invest 2006;116(8):2122-2131)

A glimpse @ the past

One year ago

Two years ago

[Back to Overwiew]  [IACM Homepage]

up

Online Events 2020

Please find all information of IACM Online Events including free videos of the webinars here.

Conference 2022

The 12th IACM Conference on Cannabinoids in Medicine will be we be held on 20 and 21 October 2022 together with the Swiss SSCM in Basel/Switzerland.

Members only

Regular members can sign up for the new member area of the IACM to access exclusive content.

You need to become a regular member of the IACM to access the new member area.

IACM on Twitter

Follow us on twitter @IACM_Bulletin where you can send us inquiries and receive updates on research studies and news articles.